Abstract:Monoclonal antibodies have many attractions as targeting agents for site-specific delivery of drugs (7). An alternative approach to chemical conjugation is to use a bispecific antibody with dual binding activity to link a toxic moiety to a binding moiety with targeting specificity. This approach is being explored with drugs (2), drug-carrier conjugates (3), and ribosome-inhibiting toxins (4,5). With such bispecific antibodies, the toxic and targeting moieties could be administered separately, with the smaller size of the separate components giving potentially advantageous tissue penetration. It would also be possible to prelocalize the antibody, giving considerable flexibility in the design of schedules for optimum localization of the toxic moiety. However, it is important to examine in vitro whether a monovalent form of an antibody against a selected tumor-associated antigen can deliver sufficient toxin of choice to an appropriate intracellular compartment to kill cells of the proposed type of target tumor. In this study, a bispecific antibody with specificities for carcinoembryonic antigen (CEA) and the A chain of ricin toxin (RTA) has been produced and examined for its ability, in the presence of RTA, to mediate selective target-cell damage against CEA-expressing gastrointestinal tract tumor cells. Bispecific antibodies can be produced by chemical conjugation of antibody fragments (5), but fusion of two hybridomas or a hybridoma with immune spleen cells (2,6-8) can produce hybridomas giving a continual supply of antibody. Hybridoma to hybridoma fusion was used in the present study, and selection of heterohybrids using a fluorescenceactivated cell sorter was found to be a rapid and convenient method of isolating hybrid hybridomas. From a fusion of an anti-RTA hybridoma (designated 596/ 192) and an anti-CEA hybridoma (NCRC-23), a hybrid hybridoma designated 636, which was found to secrete high levels of antibodies binding to CEA and RTA, was selected and recloned twice. The maximum yield of bispecific antibody from hybrid hybridomas is 50% of the total immunoglobulin synthesized, but lower proportions of bispecific antibody are produced if heterologous heavy to light chain reassociations occur (9). In the present study, we separated antibodies using agarose-encapsulated hydroxyapatite (IBF Biotechnics, Life Science Laboratories, Luton, UK): anti-RTA reactivity eluted at approximately 0.063 M phosphate, both anti-CEA and anti-RTA reactivities eluted at about 0.087 M, and binding activity for CEA alone eluted at approximately 0.158 M. Antibody fractions were then tested for their ability to bridge between CEA and RTA in a flow cytometric test. Latex beads with CEA covalently coupled to the surface (70) were mixed with putative bispecific antibody and RTA labeled with fluorescein; bound fluorescence was quantitated by flow cytometry. A positive reaction was seen in the intermediate fractions from the column, but not in the early or late fractions or the parent antibodies. Purified 636 bispecific monoclonal antibody acted synergistically with RTA to achieve highly significant cytotoxicity (table 1) at an RTA concentration as low as 4 x 10~ M against CEA-expressing MKN-45 gastric carcinoma cells. These results compare with those of independent experiments performed with chemically prepared conjugates between RTA and a different CEA-specific antibody (228). In those experiments, the most active conjugates killed 50% of MKN-45 cells at a concentration of about 1.5 X 10~ M RTA (77). The specificity of the cytotoxic effect delivered by bispecific antibody 636 was demonstrated by the lack of increased damage to 79IT cells by RTA in the presence of bispecific antibody (table 2), although this cell line is highly sensitive to RTA delivered as an immunotoxin following conjugation to an appropriate antibody (12).

Editorial: On mutants, metaphors and scientific creativity

The Serum Metabolome of COVID-19 Patients is Distinctive and Predictive

Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

Sphingolipids in Lung Pathology in the Coronavirus Disease Era: A Review of Sphingolipid Involvement in the Pathogenesis of Lung Damage

Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage

Deep phenotyping of the lipidomic response in COVID-19 and non-COVID-19 sepsis

Inverse Correlation Between Plasma Sphingosine-1-Phosphate and Ceramide Concentrations in Septic Patients and Their Utility in Predicting Mortality.

Bispecific antibody that binds carcinoembryonic antigen and ricin toxin A chain cytotoxic for gastrointestinal tract tumor cells.

Lipid Mediators and Cytokines/Chemokines Display Differential Profiles in Severe versus Mild/Moderate COVID-19 Patients

Interleukin-6 and interstitial cystitis.

Dissecting lipid metabolism alterations in SARS-CoV-2

Systematic Discovery and Pathway Analyses of Metabolic Disturbance in COVID-19

Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications

Longitudinal Metabolomics Reveals Ornithine Cycle Dysregulation Correlates With Inflammation and Coagulation in COVID-19 Severe Patients

Sulfated Bile Acids in Serum as Potential Biomarkers of Disease Severity and Mortality in COVID-19

Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis

Longitudinal Serum Proteome Characterization of COVID-19 Patients With Different Severities Revealed Potential Therapeutic Strategies

The relationship between the functional complexity and the molecular organization of the Antennapedia locus of Drosophila melanogaster.

Deciphering Cross-Cohort Metabolic Signatures of Immune Responses and Their Implications for Disease Pathogenesis

Identification of serum metabolites enhancing inflammatory responses in COVID-19

Metabolomic analyses reveal new stage-specific features of COVID-19